Eli Lilly and Company is developing its tirzepatide in heart failure and sleep apnea, in addition to obesity, in an effort to overcome payer resistance to covering drugs for weight loss, Lilly diabetes president Mike Mason explained during the company’s recent earnings presentation.
He described Phase III studies in the two indications as not aimed at expanding the patient population, since obesity is...







